Valuation: Black Diamond Therapeutics, Inc.

Market Cap 113M 98.63M 90.84M 84.25M 160M 10.77B 162M 1.09B 423M 5.29B 424M 415M 18.29B P/E 2026 *
-3.04x
P/E 2027 * -1.96x
Enterprise Value 113M 98.63M 90.84M 84.25M 160M 10.77B 162M 1.09B 423M 5.29B 424M 415M 18.29B EV / Sales 2026 *
20.3x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 15/09/2023
Chief Tech/Sci/R&D Officer 51 10/08/2021
Director of Finance/CFO 41 06/10/2024
Director TitleAgeSince
Director/Board Member 61 28/02/2017
Director/Board Member 47 30/11/2019
Director/Board Member 50 30/11/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 115M
-2.14%+3.65%+74.05%+131.89% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
-3.71%+2.97%-14.61%-13.89% 24.67B
-0.05%+7.89%+14.05%+440.15% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+7.37%+40.74%-30.67% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.57%+1.39%+20.33%+191.65% 14.04B
Average -0.05%+8.39%+54.83%+146.24% 27.28B
Weighted average by Cap. -0.71%+6.43%+57.60%+134.75%

Financials

2026 *2027 *
Net sales 5.56M 4.85M 4.47M 4.15M 7.89M 530M 7.98M 53.43M 20.8M 260M 20.86M 20.4M 900M -
Net income -40.47M -35.36M -32.57M -30.21M -57.49M -3.86B -58.16M -389M -152M -1.89B -152M -149M -6.56B -70.04M -61.2M -56.37M -52.28M -99.5M -6.68B -101M -674M -262M -3.28B -263M -257M -11.35B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.970USD
Average target price
9.857USD
Spread / Average Target
+400.36%

Quarterly revenue - Rate of surprise